BioArctic AB
BIOA-B.STDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 1 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
exidavnemab | Phase 2 | Parkinson Disease | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in BioArctic AB's drug pipeline?→
CatalystAlert tracks 1 drug candidate in BioArctic AB's (BIOA-B.ST) pipeline across Phase 2. Its lead program is exidavnemab (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BioArctic AB's next FDA catalyst?→
BioArctic AB's (BIOA-B.ST) next tracked catalyst is a Phase 2 expected August 17, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BIOA-B.ST biotech catalysts?→
Add BIOA-B.ST to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BioArctic AB's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.